Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
UroGen Pharma (NASDAQ:URGN) Upgraded to Hold by Zacks Investment Research
12:00pm, Saturday, 20'th Nov 2021 Transcript Daily
Zacks Investment Research upgraded shares of UroGen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The companys product candidates include MitoGel and []
Urogen Pharma (URGN) Investor Presentation - Slideshow
06:58pm, Friday, 19'th Nov 2021 Seeking Alpha
UroGen Pharma (NASDAQ:URGN) Issues Earnings Results, Misses Expectations By $0.09 EPS
01:30pm, Wednesday, 17'th Nov 2021 Dakota Financial News
UroGen Pharma (NASDAQ:URGN) released its earnings results on Monday. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.09), MarketWatch Earnings reports. UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. During the same quarter in the […]
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
06:19pm, Monday, 15'th Nov 2021 Seeking Alpha
UroGen Pharma slips on Q3 earnings miss and disappointing guidance
05:50pm, Monday, 15'th Nov 2021 Seeking Alpha
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
05:25pm, Monday, 15'th Nov 2021 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
01:55pm, Monday, 15'th Nov 2021
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
01:19pm, Monday, 15'th Nov 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
UroGen Pharma EPS misses by $0.06, misses on revenue
01:09pm, Monday, 15'th Nov 2021 Seeking Alpha
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
Earnings Preview: UroGen Pharma
11:02am, Friday, 12'th Nov 2021
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call Transcript
07:50am, Saturday, 07'th Aug 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call Transcript
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call Transcript
01:52pm, Thursday, 13'th May 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call Transcript
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
07:30am, Thursday, 13'th May 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call Transcript
01:54pm, Thursday, 18'th Mar 2021
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call Transcript
